Insilico Medicine and Eli Lilly published a vision paper outlining an end‑to‑end autonomous 'prompt‑to‑drug' R&D framework that chains generative AI tools into integrated discovery workflows. The proposal sketches how generative models, automation and validation can accelerate lead generation toward clinical candidates. The authors position the approach as a scalable route to higher throughput medicinal chemistry. At the same time, private companies are rolling proprietary, AlphaFold‑style generative models for drug design; Isomorphic Lab’s exclusive model drew attention and raised questions about openness and reproducibility. The juxtaposition highlights a sectoral split between open science advocates and commercial players building closed, competitive AI stacks — a dynamic that will shape access, validation standards and investment priorities in computational drug discovery.